<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726700</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL-2003-2</org_study_id>
    <secondary_id>CDR0000454473</secondary_id>
    <secondary_id>EU-20534</secondary_id>
    <nct_id>NCT00726700</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität des Saarlandes</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and&#xD;
      vincristine, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim,&#xD;
      may increase the number of immune cells found in bone marrow or peripheral blood and may help&#xD;
      the immune system recover from the side effects of chemotherapy. Monoclonal antibodies, such&#xD;
      as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them&#xD;
      or carry cancer-killing substances to them. Others interfere with the ability of cancer cells&#xD;
      to grow and spread. It is not yet known whether combination chemotherapy and pegfilgrastim is&#xD;
      more effective when given with or without rituximab in treating non-Hodgkin lymphoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving pegfilgrastim and&#xD;
      combination chemotherapy together with or without rituximab and to see how well it works in&#xD;
      treating older patients with aggressive B-cell non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the side effects of pegfilgrastim and cyclophosphamide, doxorubicin&#xD;
           hydrochloride, vincristine, and prednisone (CHOP) with or without rituximab in older&#xD;
           patients with aggressive B-cell non-Hodgkin lymphoma.&#xD;
&#xD;
        -  Determine adherence to therapy regimens in these patients.&#xD;
&#xD;
        -  Determine antitumor effectivity of immunochemotherapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      All patients receive prephase treatment comprising vincristine on day -6 and prednisone on&#xD;
      days -6 to 0. Patients are then randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (without rituximab): Patients receive pegfilgrastim subcutaneously (SC) on day 2&#xD;
           or 4 and CHOP comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and&#xD;
           vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2&#xD;
           weeks for up to 6-8 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II (with rituximab): Patients receive pegfilgrastim and CHOP for up to 6-8 courses&#xD;
           as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on&#xD;
           day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.&#xD;
&#xD;
      Patients with bulky disease or extranodal disease also undergo radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia</measure>
    <time_frame>through chemotherapy administration (up to 112 days respectively)</time_frame>
    <description>median of two measurements of hemoglobin, leukocyte and platelet counts per chemotherapy cycle per Patient in correlation with median pegfilgrastim serum levels at day 1 of the next chemotherapy cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia</measure>
    <time_frame>through chemotherapy administration (up to 112 days respectively)</time_frame>
    <description>rates and grades of leukocytopenias and infections according to NCI-CTC criteria (version 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to therapy regimens</measure>
    <time_frame>through chemotherapy administration (up to 112 days respectively)</time_frame>
    <description>the median overall treatment duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effectivity</measure>
    <time_frame>median time of observation up to 3 years</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>median time of observation up to 3 years</time_frame>
    <description>period of disease-free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (without rituximab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I (without rituximab)</arm_group_label>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (without rituximab)</arm_group_label>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (without rituximab)</arm_group_label>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (without rituximab)</arm_group_label>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (without rituximab)</arm_group_label>
    <arm_group_label>Arm II (with rituximab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of CD20-positive B-cell non-Hodgkin lymphoma (NHL)&#xD;
&#xD;
               -  Confirmed by an excisional biopsy of a lymph node or by a sufficiently extensive&#xD;
                  biopsy of an extranodal involvement (if there is no lymph node involvement)&#xD;
&#xD;
               -  Results of the immunohistological analysis of expression of the CD20 antigen by&#xD;
                  lymphoma cells must be obtained&#xD;
&#xD;
          -  Aggressive disease, including any of the following B-cell NHL&#xD;
&#xD;
               -  Stage III follicular lymphoma&#xD;
&#xD;
               -  Stage III follicular lymphoma and diffuse B-cell lymphoma&#xD;
&#xD;
               -  Lymphoblastic precursor B-cell lymphoma&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma, including any of the following subtypes:&#xD;
&#xD;
                    -  Centroblastic&#xD;
&#xD;
                    -  Immunoblastic&#xD;
&#xD;
                    -  Plasmablastic&#xD;
&#xD;
                    -  Anaplastic large cell&#xD;
&#xD;
                    -  T-cell rich B-cell lymphoma&#xD;
&#xD;
                    -  Primary effusion lymphoma&#xD;
&#xD;
                    -  Intravasal B-cell lymphoma&#xD;
&#xD;
                    -  Primary mediastinal B-cell lymphoma&#xD;
&#xD;
               -  Mantle zone lymphoma&#xD;
&#xD;
               -  Burkitt or Burkitt-like lymphoma&#xD;
&#xD;
               -  Aggressive marginal zone lymphoma (monocytoid)&#xD;
&#xD;
          -  All risk group allowed&#xD;
&#xD;
               -  Age adjusted IPI 0-3&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  No other serious concurrent diseases&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Hartmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum des Saarlandes</affiliation>
  </overall_official>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/21292644/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkin Lymphoma Study Group. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol. 2011 Aug;22(8):1872-7. doi: 10.1093/annonc/mdq674. Epub 2011 Feb 3.</citation>
    <PMID>21292644</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

